Myeloma Combination Therapy Showed Promise in Trial
A small study found that combining two newer therapies for multiple myeloma resulted in high response rates.
Updated on Sept. 23, 2026 in Cancer
Live Poll
Do you believe new medical drug combinations generally offer better outcomes for patients?
In a preliminary phase 1b/2 study, researchers evaluated the combination of mezigdomide and elranatamab for patients with relapsed or refractory multiple myeloma. While early results were positive, the study included only 13 evaluable patients, and research remains ongoing.
Why it matters
Managing multiple myeloma that has stopped responding to initial treatments is a significant clinical challenge. This research explores whether combining these therapies can overcome resistance and improve outcomes for patients with limited options.
In a phase 1b/2 trial, 13 evaluable patients with relapsed or refractory multiple myeloma received a combination of mezigdomide and elranatamab. Preliminary findings showed a 100% objective response rate, though larger studies are required to confirm these results.
The players
International Myeloma Society
A global professional organization dedicated to advancing research and clinical care for myeloma patients.
The details
The treatment combines mezigdomide, a CELMoD agent, with the bispecific antibody elranatamab. Researchers designed this pairing to restore T-cell fitness and reverse exhaustion in the immune system, theoretically allowing the body to better combat a high tumor burden. Side effects reported in the small cohort included fatigue and neutropenia, which occurred in 84.6 percent of patients.
Timeline
Patients were enrolled between December 2024 and October 2025.
Results were presented in 2026 at the International Myeloma Society Annual Meeting.
Health Landscape
This research builds on the ongoing development of combination immunotherapies for hematologic malignancies. It marks a push to improve patient outcomes by pairing next-generation agents to circumvent the resistance patterns frequently seen in refractory myeloma.
These findings are preliminary and currently limited to a small group of patients in a clinical trial. If you are managing relapsed multiple myeloma, it is worth discussing available clinical trials and the potential for combination therapies with your oncologist.
The takeaway
Combination therapies aim to improve outcomes by addressing tumor resistance mechanisms from multiple angles. Patients should monitor for updates from ongoing clinical trials and discuss the latest therapeutic options with their primary care physician or hematologist.
What happens next
Part 2 of the MELT-MM trial is currently enrolling patients in Singapore and Korea to further compare 0.3-mg and 0.6-mg mezigdomide dosing cohorts.
Further reading
For more information on the latest research and standard care for hematologic malignancies, visit our Cancer section.
More information
View the official MELT-MM clinical trial record for more details.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe new medical drug combinations generally offer better outcomes for patients?
